← All stocks

Sagimet Biosciences Inc.

SGMT Net selling

CIK 0001400118 #2909 in the set updated 17 Sep 2026

Bought (12 mo)

$0.00

out of their own pocket, the only kind of buying there is

Sold (12 mo)

$4.91M

$430.51K on a plan · $3.79M straight out of an exercise

Sold at will

$684.36K

6 of 10 sales

Net

−$4.91M

−$684.36K against sales at will

By person

5 insiders · 10 transactions

12.0×

David Happel holds 12.0 times base salary in stock. $7.59M of shares against $630.00K in salary for 2025.

Salary from the company's own proxy. The shares are what David Happel last reported holding, valued at $10.23, the price Series A Common Stock was last bought or sold at on the open market here, on 14 Aug 2026.

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Kemble George

Director

—

$4.22M (4) scheduled

−$4.22M

62,161

0.2026%

$636.08K

−47.6%

Happel David

President & CEO

—

$561.93K (2)

−$561.93K

741,570

2.42%

$7.59M

+16.0%

Rozek Elizabeth

Chief Legal & Admin. Officer

—

$95.89K (2)

−$95.89K

224,414

0.7316%

$2.30M

+39.8%

Martins Eduardo Bruno

Chief Medical Officer

—

$19.51K (1)

−$19.51K

147,296

0.4802%

$1.51M

+81.4%

Chauche Thierry

Chief Financial Officer

—

$7.03K (1)

−$7.03K

59,688

0.1946%

$610.78K

—

Individual transactions

Nothing of that kind in this period.

What was left out

Form 4 filings counted 26

Amendments (4/A) skipped 0

Filings about a different issuer 0

Unreadable filings 0

Joint filings 0

Sales on a Rule 10b5-1 plan 2

Sales straight out of an exercise 2

Sales at will 6

Transactions with no price 0

Shares from compensation/vesting 641,048

History held since 20 Jul 2023